All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Loading...
| CAT | Product Name | Target Species | TCR Clone | Host Species | Epitope | Allele | Vector Type | Inquiry & Datasheet |
| TCR-C264 | Human anti-Beryllium sulfate T cell receptor (CB-C004), pCDTCR1 | CB-C004 | Human | FWIDLFETIG | HLA-DPB1*02:01 | Lentiviral vector | ||
| TCR-C265 | Human anti-Beryllium sulfate T cell receptor (CB-C005), pCDTCR1 | CB-C005 | Human | FWIDLFETIG | HLA-DPB1*02:01 | Lentiviral vector | ||
| TCR-YC0120 | Human anti-Beryllium Sulfate T cell receptor (1041-3.3), pCDTCR1 | 1041-3.3 | Human | Beryllium sulfate | HLA-DPB1*02:01 | Lentiviral vector | ||
| TCR-YC0121 | Human anti-Beryllium Sulfate T cell receptor (1332-2), pCDTCR1 | 1332-2 | Human | Beryllium sulfate | HLA-DPB1*02:01 | Lentiviral vector | ||
| TCR-YC0122 | Human anti-Beryllium Sulfate T cell receptor (1332-2 Valpha R53A), pCDTCR1 | 1332-2 Valpha R53A | Human | Beryllium sulfate | HLA-DPB1*02:01 | Lentiviral vector | ||
| TCR-YC0123 | Human anti-Beryllium Sulfate T cell receptor (1332-2 Valpha S30A), pCDTCR1 | 1332-2 Valpha S30A | Human | Beryllium sulfate | HLA-DPB1*02:01 | Lentiviral vector | ||
| TCR-YC0124 | Human anti-Beryllium Sulfate T cell receptor (1332-22), pCDTCR1 | 1332-22 | Human | Beryllium sulfate | HLA-DPB1*02:01 | Lentiviral vector | ||
| TCR-YC0125 | Human anti-Beryllium Sulfate T cell receptor (1332-22 Valpha N53A), pCDTCR1 | 1332-22 Valpha N53A | Human | Beryllium sulfate | HLA-DPB1*02:01 | Lentiviral vector | ||
| TCR-YC0126 | Human anti-Beryllium Sulfate T cell receptor (1332-22 Valpha S30A), pCDTCR1 | 1332-22 Valpha S30A | Human | Beryllium sulfate | HLA-DPB1*02:01 | Lentiviral vector | ||
| TCR-YC0127 | Human anti-Beryllium Sulfate T cell receptor (1332-22 Vbeta K101A), pCDTCR1 | 1332-22 Vbeta K101A | Human | Beryllium sulfate | HLA-DPB1*02:01 | Lentiviral vector | ||
| TCR-YC0128 | Human anti-Beryllium Sulfate T cell receptor (1332-22 Vbeta S99A), pCDTCR1 | 1332-22 Vbeta S99A | Human | Beryllium sulfate | HLA-DPB1*02:01 | Lentiviral vector | ||
| TCR-YC0129 | Human anti-Beryllium Sulfate T cell receptor (1332-28), pCDTCR1 | 1332-28 | Human | Beryllium sulfate | HLA-DPB1*02:01 | Lentiviral vector | ||
| TCR-YC0130 | Human anti-Beryllium Sulfate T cell receptor (1332-28 Valpha D54A), pCDTCR1 | 1332-28 Valpha D54A | Human | Beryllium sulfate | HLA-DPB1*02:01 | Lentiviral vector | ||
| TCR-YC0131 | Human anti-Beryllium Sulfate T cell receptor (1332-28 Valpha D55A), pCDTCR1 | 1332-28 Valpha D55A | Human | Beryllium sulfate | HLA-DPB1*02:01 | Lentiviral vector | ||
| TCR-YC0132 | Human anti-Beryllium Sulfate T cell receptor (1332-28 Valpha G57A), pCDTCR1 | 1332-28 Valpha G57A | Human | Beryllium sulfate | HLA-DPB1*02:01 | Lentiviral vector | ||
| TCR-YC0133 | Human anti-Beryllium Sulfate T cell receptor (1332-28 Valpha G97A), pCDTCR1 | 1332-28 Valpha G97A | Human | Beryllium sulfate | HLA-DPB1*02:01 | Lentiviral vector | ||
| TCR-YC0134 | Human anti-Beryllium Sulfate T cell receptor (1332-28 Vbeta E100A), pCDTCR1 | 1332-28 Vbeta E100A | Human | Beryllium sulfate | HLA-DPB1*02:01 | Lentiviral vector | ||
| TCR-YC0135 | Human anti-Beryllium Sulfate T cell receptor (1332-28 Vbeta E48A), pCDTCR1 | 1332-28 Vbeta E48A | Human | Beryllium sulfate | HLA-DPB1*02:01 | Lentiviral vector | ||
| TCR-YC0136 | Human anti-Beryllium Sulfate T cell receptor (1332-28 Vbeta E52A), pCDTCR1 | 1332-28 Vbeta E52A | Human | Beryllium sulfate | HLA-DPB1*02:01 | Lentiviral vector | ||
| TCR-YC0137 | Human anti-Beryllium Sulfate T cell receptor (1332-28 Vbeta G98A), pCDTCR1 | 1332-28 Vbeta G98A | Human | Beryllium sulfate | HLA-DPB1*02:01 | Lentiviral vector |
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION